Menu Search
Equities

Shenzhen Chipscreen Biosciences Co Ltd

688321:SHH

Shenzhen Chipscreen Biosciences Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)15.28
  • Today's Change-0.58 / -3.66%
  • Shares traded2.36m
  • 1 Year change-32.30%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Shenzhen Chipscreen Biosciences Co Ltd had relatively flat revenues (529.94m to 523.71m), though the company grew net income 408.09% from 17.48m to 88.84m.
Gross margin86.55%
Net profit margin-18.46%
Operating margin-17.26%
Return on assets-3.34%
Return on equity-6.28%
Return on investment-3.78%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Shenzhen Chipscreen Biosciences Co Ltd fell by 148.58m. Cash Flow from Financing totalled 382.62m or 73.06% of revenues. In addition the company used 157.27m for operations while cash used for investing totalled 375.01m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.06
Tangible book value per share2.46
More ▼

Balance sheet in CNYView more

Shenzhen Chipscreen Biosciences Co Ltd has a Debt to Total Capital ratio of 41.88%, a lower figure than the previous year's 46.06%.
Current ratio2.84
Quick ratio2.71
Total debt/total equity0.7205
Total debt/total capital0.4188
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 402.79%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)20.07
EPS (TTM) vs
TTM 1 year ago		-154.63
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.